Crinetics Pharmaceuticals’ Phase 3 Study Achieves Primary and Secondary Endpoints

Crinetics Pharmaceuticals (Nasdaq: CRNX) has achieved all primary and secondary endpoints in its Phase 3 PATHFNDR-1 study of paltusotine as a once-daily treatment for acromegaly, a serious rare disease. The company’s share price soared nearly 65% following the news.

Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, said, “We could not be more excited by the results from PATHFNDR-1, which further reinforce our conviction that, if approved, paltusotine could address patients’ unmet need for a simple, oral, once-daily therapy. These data showed that upon switching from injected standard of care, paltusotine provided reliable, durable control of their disease. We intend to seek regulatory approval as quickly as possible once we complete the PATHFNDR-2 study early next year.”

PATHFNDR-2, a Phase 3 study of oral paltusotine in participants with acromegaly who are treatment-naïve or not currently receiving medical therapy, is fully enrolled and topline data are expected in the first quarter of 2024.


The study met statistical significance (p<0.0001) on the primary endpoint, based on the proportion of participants taking paltusotine (83%) who maintained an insulin-like growth factor 1 (IGF-1) level ≤ 1.0 times the upper limit of normal (xULN) compared to those taking placebo (4%).

Paltusotine was well tolerated with no serious or severe adverse events reported.

A full analysis of the PATHFNDR-1 results is underway, which the company expects to present at upcoming scientific conferences.

Crinetics plans to submit a new drug application to the U.S. Food and Drug Administration in 2024 seeking regulatory approval.

PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies of once-daily, oral paltusotine.

Acromegaly is generally caused by a benign pituitary adenoma that secretes growth hormone (GH). Excess GH secretion causes excess secretion of IGF-1 from the liver. Prolonged exposure to increased levels of IGF-1 and GH leads to progressive and serious systemic complications.


About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894 a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of Cushing’s disease and congenital adrenal hyperplasia. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.

Share This Article


About the Author

Crinetics Pharmaceuticals’ Phase 3 Study Achieves Primary and Secondary Endpoints

Catie Corcoran

Biotech Editor